AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$JUNS

JUPITER NEUROSCIENCES, INC.

Price · $JUNSvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $JUNS in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $JUNS in the last 30 days.

Top stories · $JUNSMore →
APR 9·The National Law ReviewMed

Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) has appointed Kristopher Fishman and Sanjiv Lal to its Nugevia™ Advisory Board. These appointments aim to strengthen Jupiter's entry into the over $1.5 billion nutraceutical market by leveraging the new advisors' expertise in nationwide pharmacy and wellness distribution channels. Nugevia™ is Jupiter's consumer longevity product line, based on its patented JOTROL™ micellar delivery technology, which is also used in its clinical pipeline.

JAN 28·GlobeNewswire

Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users

Jupiter Neurosciences is expanding the market for its Nugevia™ longevity product line to support individuals using GLP-1-based weight loss therapies. The company believes Nugevia™ can address unmet needs related to mitochondrial energy production, lean tissue preservation, and neuro-gut inflammatory balance, which can be stressed during GLP-1-induced weight loss. This strategy combines their clinical-stage pharmaceutical pipeline with a direct-to-consumer longevity business, both powered by their proprietary JOTROL™ resveratrol formulation.

News on $JUNS

All news →